Trial Profile
Phase II Trial of CC-5013 in Patients With Advanced Renal Cell Carcinoma With Either No Prior Treatment or One Prior Treatment Regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2013
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 01 Sep 2005 New trial record.